Loading…

Vigorous physical activity provides protection against all‐cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)

Summary Background Mortality benefits of vigorous leisure time physical activity (LTPA) among adults with NAFLD is not known. Aim To investigate association between LTPA and reduction in all‐cause mortality among adults with NAFLD. Methods We used NHANES (1999–2006) self‐reported PA data for adults...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2023-03, Vol.57 (6), p.709-722
Main Authors: Henry, Austin, Paik, James M., Austin, Patrick, Eberly, Katherine Elizabeth, Golabi, Pegah, Younossi, Issah, Henry, Linda, Gerber, Lynn, Younossi, Zobair M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Mortality benefits of vigorous leisure time physical activity (LTPA) among adults with NAFLD is not known. Aim To investigate association between LTPA and reduction in all‐cause mortality among adults with NAFLD. Methods We used NHANES (1999–2006) self‐reported PA data for adults (≥40 years) with mortality follow‐up through December 31, 2015. US‐Fatty Liver Index in absence of secondary causes identified NAFLD. Moderate and vigorous LTPA were calculated by the 2018 PA Guidelines for Americans. Results NAFLD prevalence among 5211 adults (46.2% male; 75.8% white; mean age 53.2 years) was 32.7%. Adults with NAFLD were less likely to report the recommended minimal PA (≥ 150 min/week, 55.5% vs 64.8%) or highly active PA (≥300 min/week, 39.2% vs 48.5%) compared to adults without NAFLD. Over a median follow‐up of 12.3 years, 355 deaths among adults with NAFLD and 510 deaths among adults without NAFLD were registered. In the metabolic comorbidities‐adjusted model, adults with NAFLD who reported ≥50% of their total PA as vigorous activity had a 56% reduction in all‐cause mortality risk (HR:0.44, 95%CI: 0.25–0.76) and cancer‐specific mortality risk (HR: 0.21, 0.06–0.66) but not cardiac‐specific mortality (p > 0.05) compared to adults with NAFLD who did not report any LTPA. This association remained significant even among adults with NAFLD who met the recommended minimal PA, among adults with NAFLD who reported any LTPA, and among adults with NAFLD who had metabolic abnormalities and in sensitivity analysis. Conclusions Engaging in vigorous activity is beneficial for adults with NAFLD ‐ especially those with metabolic abnormalities. Is vigorous activity associated with a reduction in mortality among adults with NAFLD?
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.17308